Αρχική World News EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide

EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide

On 23 July 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product arsenic trioxide (Arsenic trioxide medac), intended for the treatment of acute promyelocytic leukaemia (APL).

The applicant for this medicinal product is medac Gesellschaft für klinische Spezialpräparate mbH.

Arsenic trioxide medac will be available as 1 mg/ml concentrate for solution for infusion. The active substance of Arsenic trioxide medac is arsenic trioxide, an antineoplastic agent (ATC code: L01XX27). The mechanism of action of arsenic trioxide is not completely understood but it causes fragmentation, damage or degradation of DNA and the fusion protein pro-myelocytic leukaemia/retinoic acid receptor-alpha (PML/RAR-alpha) in promyelocytic leukaemia cells.

Arsenic trioxide medac is a generic of Trisenox, which has been authorised in the EU since 5 March 2002. Since Arsenic trioxide medac is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Trisenox was not required.

The full indication is:

Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:

  • Newly diagnosed low-to-intermediate risk APL (white blood cell count, ≤10 x 10³/µl) in combination with all-trans-retinoic acid (ATRA)
  • Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy)

characterised by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.

The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Arsenic trioxide medac should be prescribed by physicians experienced in the treatment of acute leukaemias.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the European Commission decision, which will normally be issued 67 days from adoption of the opinion.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Beating cancer by improving the public’s health: the road ahead in England

Every year, around 367,000 people are diagnosed with cancer in the UK. Around 4 in 10 of those cancers are caused by things we...

How People With Cancer Can Make the Most of Televisits

Carolyn B. Hendricks, MD, FASCO, is a breast-dedicated medical oncologist in community practice in Bethesda, Maryland. She did all of her medical training at...

Want to learn more about Sulforaphanes?

Sulforaphanes are a class of phytochemical. A phytochemical is: A product from plants that is not a vitamin or mineral No known required amount in the...

Gift Giving During a Pandemic

Finding the right gift to give a cancer patient or their loved ones can be challenging…and now let’s add a pandemic to the mix....

Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC

The KEYNOTE-177 study investigators reported on 3 December 2020 in The New England Journal of Medicine that the study data represent another step forward...

Keeping progress in oncology on the agenda: ESMO honours recipients of its 2020 awards

The global coronavirus pandemic has disrupted cancer research, prevention and treatment to an extent never seen before. Date: 03 Dec 2020 LUGANO, Switzerland - The global...